Changes in Plasma Levels of Asymmetric Dimethylarginine in Chronic Kidney Disease Patients Treated for 8 Weeks with the Vitamin D Receptor Agonist Paricalcitol
نویسندگان
چکیده
Abbreviations: VDRA: Vitamin D Receptor Agonist; ADMA: Asymmetric Dimethylarginine; ICAM: Soluble Intracellular Adhesion Molecule; VCAM: Vascular Adhesion Molecule; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; VEGF: Vascular Endothelial Growth Factor; MCP-1: Monocyte Chemoattractant Protein; IL-1: Interleukin-1; IL-6: Interleukin-6; TNFα: Tumor Necrosis Factor-α; CKD: Chronic Kidney Disease; eGFR: Estimated Glomerular Filtration Rate; PTH: Parathyroid Hormone
منابع مشابه
Vitamin D and methylarginines in chronic kidney disease (CKD)
BACKGROUND Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug. METHODS In the frame of a randomized, double-blind, plac...
متن کاملAsymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
Introduction Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidney disease and more specifically those on hemodialysis, cardiovascular events are the...
متن کاملParicalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
Patients with chronic kidney disease are often insulin resistant and glucose intolerant--abnormalities that promote cardiovascular disease. Administration of 1,25-dihydroxyvitamin D (calcitriol) has improved glucose metabolism in patients with end-stage renal disease. We conducted a randomized, placebo-controlled clinical trial to test whether paricalcitol, a 1,25-dihydroxyvitamin D analog, cha...
متن کاملVitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease – a randomized trial
BACKGROUND Chronic kidney disease (CKD) is a major risk factor for cardiovascular disease (CVD), partly due to endothelial dysfunction and chronic inflammation. Vitamin D treatment in end stage renal disease is suggested to modulate the immune system and lead to improved outcomes. We and others have demonstrated that treatment with vitamin D or activated vitamin D analogues protects the endothe...
متن کاملThe Efficacy of Paricalcitol Administration for Management of Pediatric Chronic Kidney Disease: A Systematic Review and Meta-analysis
Background There is still controversy about the efficacy of paricalcitol in children with chronic kidney disease (CKD). Therefore, the present study was designed to assess current evidence on the efficacy of paricalcitol in CKD children. Materials and Methods <span lang="EN-...
متن کامل